MA51844A - Méthodes de traitement du cancer avec des anticorps anti pd-1 et des anticorps anti ctla4 - Google Patents

Méthodes de traitement du cancer avec des anticorps anti pd-1 et des anticorps anti ctla4

Info

Publication number
MA51844A
MA51844A MA051844A MA51844A MA51844A MA 51844 A MA51844 A MA 51844A MA 051844 A MA051844 A MA 051844A MA 51844 A MA51844 A MA 51844A MA 51844 A MA51844 A MA 51844A
Authority
MA
Morocco
Prior art keywords
antibodies
cancer treatment
treatment methods
ctla4
ctla4 antibodies
Prior art date
Application number
MA051844A
Other languages
English (en)
French (fr)
Inventor
Rachel Allison Altura
Lokesh Jain
Mallika Lala
Mengyao Li
Archie Ngai-Chiu Tse
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA51844A publication Critical patent/MA51844A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA051844A 2018-02-13 2019-02-08 Méthodes de traitement du cancer avec des anticorps anti pd-1 et des anticorps anti ctla4 MA51844A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862630038P 2018-02-13 2018-02-13
US201862732828P 2018-09-18 2018-09-18
US201862740741P 2018-10-03 2018-10-03

Publications (1)

Publication Number Publication Date
MA51844A true MA51844A (fr) 2021-05-19

Family

ID=67620098

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051844A MA51844A (fr) 2018-02-13 2019-02-08 Méthodes de traitement du cancer avec des anticorps anti pd-1 et des anticorps anti ctla4

Country Status (11)

Country Link
US (1) US20210047409A1 (enExample)
EP (1) EP3752193A4 (enExample)
JP (2) JP2021513540A (enExample)
KR (1) KR20200119845A (enExample)
CN (2) CN111727056A (enExample)
AU (2) AU2019222517A1 (enExample)
BR (1) BR112020015915A8 (enExample)
CA (1) CA3090996A1 (enExample)
MA (1) MA51844A (enExample)
MX (1) MX2020008446A (enExample)
WO (1) WO2019160755A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
WO2020185722A2 (en) * 2019-03-13 2020-09-17 Merck Sharp & Dohme Corp. Anti-cancer combination therapies comprising ctla-4 and pd-1 blocking agents
CN113244385A (zh) * 2020-02-07 2021-08-13 上海君实生物医药科技股份有限公司 抗pd-1抗体在治疗恶性肿瘤中的用途
US20230118596A1 (en) * 2020-03-05 2023-04-20 Merck Sharp & Dohme Llc Methods for treating cancer using a combination of a pd-1 antagonist, a ctla4 antagonist, and lenvatinib or a pharmaceutically accpetable salt thereof
EP4114863A4 (en) * 2020-03-05 2024-04-24 Merck Sharp & Dohme LLC METHODS OF TREATING CANCER OR INFECTION USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY, AN ANTI-CTLA4 ANTIBODY AND AN ANTI-TIGIT ANTIBODY
WO2021213523A1 (zh) * 2020-04-24 2021-10-28 信达生物制药(苏州)有限公司 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途
TW202305009A (zh) * 2021-04-08 2023-02-01 美商默沙東有限責任公司 以皮下投予抗pd1抗體治療癌症之方法
IL310201A (en) * 2021-07-19 2024-03-01 Regeneron Pharma Combination of inhibitor-control inhibitor and oncolytic virus for cancer treatment
JP2024540152A (ja) * 2021-10-29 2024-10-31 オンコシーフォー、インク． 抗ｃｔｌａ－４抗体投与レジメン
CN113933520B (zh) * 2021-11-15 2023-06-20 邹灵龙 一种通用型抗体药血药浓度检测的单克隆抗体试剂组合、检测方法和试剂盒
US20250376525A1 (en) * 2022-06-28 2025-12-11 Qilu Pharmaceutical Co., Ltd. Pharmaceutical composition comprising mixed antibody of anti-ctla4 and anti-pd1 and therapeutic use thereof
EP4583981A2 (en) * 2022-09-09 2025-07-16 Adagene Pte. Ltd. Activatable anti-ctla4 antibodies for treating cancer
CN118767127A (zh) * 2023-04-10 2024-10-15 康方药业有限公司 抗ctla4-抗pd-1双特异性抗体的医药用途
CN121816195A (zh) * 2023-08-21 2026-04-07 艾吉纳斯公司 使用ctla-4抑制剂和pd-1抑制剂的组合治疗结直肠癌的方法
TW202511295A (zh) * 2023-08-31 2025-03-16 大陸商江蘇恆瑞醫藥股份有限公司 Ｃｔｌａ４／ｔｉｇｉｔ結合蛋白及其醫藥用途
WO2026021409A1 (zh) * 2024-07-22 2026-01-29 宜明昂科生物医药技术（上海）股份有限公司 靶向ctla-4、pd-l1和vegf的肿瘤联合疗法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1212422B1 (en) * 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
DK2439273T3 (da) * 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
BR122017025062B8 (pt) * 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
AR095199A1 (es) * 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
CN105296433B (zh) * 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
US10695426B2 (en) * 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
JP2018515474A (ja) * 2015-04-28 2018-06-14 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置
EP3322731B1 (en) * 2015-07-14 2021-01-13 Bristol-Myers Squibb Company Method of treating cancer using immune checkpoint inhibitor; antibody that binds to programmed death-1 receptor (pd-1) or programmed death ligand 1 (pd-l1)
US20180222989A1 (en) * 2015-08-04 2018-08-09 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
US20180230431A1 (en) * 2015-08-07 2018-08-16 Glaxosmithkline Intellectual Property Development Limited Combination Therapy
ES2986067T3 (es) * 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas
US10358496B2 (en) * 2016-03-01 2019-07-23 Ralf Kleef Low dose immune checkpoint blockade in metastatic cancer
ES2954139T3 (es) * 2016-06-02 2023-11-20 Bristol Myers Squibb Co Bloqueo de PD-1 con nivolumab en el linfoma de Hodgkin refractario
CN109476753A (zh) * 2016-06-03 2019-03-15 百时美施贵宝公司 用于治疗肿瘤的方法的抗-pd-1抗体
JP2019517512A (ja) * 2016-06-03 2019-06-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 結腸直腸癌を有する患者の処置における抗ｐｄ−１抗体の使用
JP2020518598A (ja) * 2017-05-02 2020-06-25 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 単独およびプログラム死受容体１（ｐｄ−１）抗体と組み合わされた抗ｃｔｌａ４抗体の安定な製剤、ならびにその使用方法

Also Published As

Publication number Publication date
CN119792515A (zh) 2025-04-11
JP2021513540A (ja) 2021-05-27
JP2024038250A (ja) 2024-03-19
AU2023208115A1 (en) 2024-01-18
EP3752193A4 (en) 2022-02-23
CN111727056A (zh) 2020-09-29
BR112020015915A2 (pt) 2020-12-15
WO2019160755A1 (en) 2019-08-22
RU2020129075A (ru) 2022-03-14
US20210047409A1 (en) 2021-02-18
BR112020015915A8 (pt) 2023-01-31
EP3752193A1 (en) 2020-12-23
MX2020008446A (es) 2020-09-28
CA3090996A1 (en) 2019-08-22
AU2019222517A1 (en) 2020-08-13
KR20200119845A (ko) 2020-10-20

Similar Documents

Publication Publication Date Title
MA51844A (fr) Méthodes de traitement du cancer avec des anticorps anti pd-1 et des anticorps anti ctla4
MA52962A (fr) Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1
EP3752180A4 (en) METHOD OF TREATMENT OF CANCER WITH ANTI-PD-1 ANTIBODIES
MA51631A (fr) Anticorps anti-pd1 et méthodes de traitement
PL3458478T3 (pl) Przeciwciała anty pd-1 i anty-lag3 do leczenia nowotworu
MA47206A (fr) Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3
EP3687981A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF CANCER
EP3494142A4 (en) ANTI-SIGLEC-7 ANTIBODIES FOR TREATING CANCER
MA47208A (fr) Procédés de traitement du cancer à l'aide d'anticorps anti-pd-1
EP3573658A4 (en) ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR TREATMENT OF ACTIVE PSORIATIC ARTHRITIS
MA51815A (fr) Méthodes de traitement ou de prévention de migraines avec anticorps contra le receptor de cgrp
EP3400013A4 (en) CADHERIN-17 SPECIFIC ANTIBODIES AND CYTOTOXIC CELL TREATMENT CELLS
MA53506A (fr) Méthodes de traitement du cancer avec des inhibiteurs de pd-l1 à petites molécules
EP2849785A4 (en) METHOD FOR THE TREATMENT OF CANCER WITH NOTCH2 / 3 ANTIBODIES
MA46842A (fr) Méthodes de traitement de l'obésité au moyen d'anticorps anti-angptl8
EP3462883A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
MA55717A (fr) Méthodes de traitement du cancer de la prostate avec un anticorps anti-psma/cd3
EP3681498A4 (en) PROCEDURES AND COMPOSITIONS FOR CANCER TREATMENT
EP3688023A4 (en) PROCEDURES AND COMPOSITIONS FOR CANCER TREATMENT
EP3638293A4 (en) METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER
EP3870104A4 (en) METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
EP3873205A4 (en) MATERIALS AND METHODS FOR TREATMENT OF CANCER
EP3773625A4 (en) METHODS AND MATERIALS FOR TREATMENT OF CANCER
EP3679123A4 (en) BACTERIA FOR TARGETING TUMORS AND TREATING CANCER
EP3652195A4 (en) PEPTID-SAPORINE CONJUGATE FOR THE TREATMENT OF CANCER